• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

验证数据展示

  • FC experiment of human PBMCs using 98139-1-RR

    FC experiment of human PBMCs using 98139-1-RR

    1x10^6 untreated or IFN-α treated human PBMCs were surface stained with 0.25 ug Anti-Human TRAIL/CD253 Rabbit RecAb (98139-1-RR, Clone: 241419D2) and PE-Conjugated Goat Anti-Rabbit IgG(H+L). Cells were co-stained with CoraLite® Plus 647 Anti-Human CD14 Rabbit Recombinant Antibody (CL647-98040, Clone: 230332D7). Cells were incubated with FC Receptor Block prior to staining. Cells were not fixed.

  • FC experiment of human PBMCs using 98139-1-RR

    FC experiment of human PBMCs using 98139-1-RR

    1x10^6 IFN-α treated human PBMCs were surface stained with 0.25 ug Anti-Human TRAIL/CD253 Rabbit RecAb (98139-1-RR, Clone: 241419D2) (red) or 0.25 ug Rabbit IgG Isotype Control RecAb (98136-1-RR, Clone: 240953C9) (blue), and PE-Conjugated Goat Anti-Rabbit IgG(H+L). 1x10^6 untreated human PBMCs were surface stained with 0.25 ug Anti-Human TRAIL/CD253 Rabbit RecAb (98139-1-RR, Clone: 241419D2) (black, dashed) and PE-Conjugated Goat Anti-Rabbit IgG(H+L). Cells were incubated with FC Receptor Block prior to staining. Cells were not fixed.

  • Affinity and Kinetic Characterization of 98139-1-RR

    Affinity and Kinetic Characterization of 98139-1-RR

    Biolayer interferometry (BLl) kinetic assays of 98139-1-RR against Human TRAIL/CD253 were performed. The affinity constant is below 1 pM.

Anti-Human TRAIL/CD253 Rabbit Recombinant Antibody

TRAIL/CD253 Recombinant Antibody for FC
Cat No. 98139-1-RR

产品说明书

CloneNo. 241419D2

宿主/亚型

Rabbit / IgG

种属反应性

human

应用

FC

别名

TNFSF10, TRAIL, 241419D2, Apo-2 ligand, CD253

缓冲液配方:  PBS and Azide
PBS and Azide
PBS Only
偶联物:  Unconjugated
Unconjugated
规格价格库存

点击咨询售前客服

点击咨询售后客服

经过测试的应用

Positive FC detected inIFN-alpha treated human PBMCs

推荐稀释比

应用推荐稀释比
Flow Cytometry (FC)FC : 0.25 ug per 10^6 cells in a 100 µl suspension
This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

产品信息

98139-1-RR targets TRAIL/CD253 in FC applications and shows reactivity with human samples.

经测试应用 FC Application Description
经测试反应性 human
免疫原 Recombinant Protein 种属同源性预测
宿主/亚型 Rabbit / IgG
抗体类别 Recombinant
产品类型 Antibody
全称 tumor necrosis factor (ligand) superfamily, member 10
别名 TNFSF10, TRAIL, 241419D2, Apo-2 ligand, CD253
计算分子量 281 aa, 33 kDa
GenBank蛋白编号BC032722
基因名称 TRAIL
Gene ID (NCBI) 8743
RRIDAB_3672285
偶联类型 Unconjugated
形式Liquid
纯化方式Protein A purfication
UNIPROT IDP50591
储存缓冲液 PBS with 0.09% sodium azide, pH 7.3.
储存条件Store at 2 - 8°C. Stable for one year after shipment.

背景介绍

TRAIL, also known as CD253 or TNFSF10 (tumor necrosis factor superfamily member 10), is a typical death ligand expressed on natural killer cells and cytotoxic T lymphocytes. This protein preferentially induces apoptosis in transformed and tumor cells, but does not appear to kill normal cells although it is expressed at a significant level in most normal tissues. TRAIL induces apoptotic cell death in cancer by binding to its functional death receptors, death receptor (DR) 4 (TNFRSF10A/TRAIL-R1) and DR5 (TNFRSF10B/TRAIL-R2) to activate the extrinsic apoptosis pathway. TRAIL also activates c-Jun N-terminal kinase (MAPK8/JNK) and the transcription factor nuclear factor-κB (NFκB). The binding of this protein to its receptors has been shown to trigger the activation of MAPK8/JNK, caspase 8, and caspase 3.

实验方案

Product Specific Protocols
FC protocol for TRAIL/CD253 antibody 98139-1-RRDownload protocol
Standard Protocols
Click here to view our Standard Protocols